Read by QxMD icon Read

Stage I seminoma

Hiromichi Katayama, Hiroshi Aoki, Katsuyuki Taguchi, Yuu Sakurada, Tomonori Sato, Masahiro Takahashi, Rie Shibuya, Hiroshi Naganuma, Shigeto Ishidoya
We report a histologically pure stage 1 seminoma with an elevated human chorionic gonadotropin (hCG). A 38 year-old man was referred for the evaluation of the left testicular swelling. He showed an elevated serum hCG level of 25,265 mIU/ml with normal a fetoprotein and lactate dehydrogenase. Imaging showed heterogeneous tumor without any metastatic lesions. We conducted 4 courses of chemotherapy before detecting hCG nadir. The final pathological report showed pure seminoma with syncytiotrophoblastic cells but no choriocarcinoma components...
November 2016: Urology Case Reports
Madhur Nayan, Michael A S Jewett, Lynn Anson-Cartwright, Philippe L Bedard, Malcolm Moore, Peter Chung, Padraig Warde, Joan Sweet, Martin O'Malley, Robert J Hamilton
INTRODUCTION: Institutional experience has been associated with improved outcomes for various malignancies, including testicular cancer. The present study evaluated whether institution at orchiectomy was associated with outcomes on active surveillance (AS) for clinical stage (CS) I germ cell tumours (GCT). METHODS: 815 patients with CSI GCT managed with AS at the Princess Margaret Cancer Centre were identified. Princess Margaret is a tertiary academic institution with a multidisciplinary testicular cancer clinic involving radiation oncologists, medical oncologists, and urologists, and has research experience in testicular cancer care...
May 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
Wee Loon Ong, Lester Nazareth, Benjamin Hindson, Bronwyn Matheson, Jeremy L Millar
INTRODUCTION: The aim of the study is to review the long-term oncological outcomes and adverse effects of post-operative radiotherapy (PORT) for Stage I/II seminoma patients in an Australian radiation treatment centre. METHODS: This is a retrospective study of 125 patients with Stage I/II seminoma treated with PORT at the Alfred Health Radiation Oncology Service between 1992 and 2013. Patients were linked to the Victorian Cancer Registry to enable confirmation of survival and diagnosis of secondary malignancies (SM)...
September 2016: Journal of Medical Radiation Sciences
Michal Chovanec, Nasser Hanna, K Clint Cary, Lawrence Einhorn, Costantine Albany
Clinical stage I testicular germ cell tumours (TGCT) are highly curable neoplasms. The treatment of stage I testicular cancer is complex and requires a multidisciplinary approach. Standard options after radical orchiectomy for seminoma include active surveillance, radiation therapy or 1-2 cycles of carboplatin, and options for nonseminoma include active surveillance, retroperitoneal lymph node dissection (RPLND) or 1-2 cycles of bleomycin plus etoposide plus cisplatin (BEP). All the options should be discussed with each patient and treatment choices should be made by shared decision making as virtually all patients with clinical stage I TGCT can be cured of their disease...
September 13, 2016: Nature Reviews. Urology
Francesca De Felice, Daniela Musio, Giovanni Luca Gravina, Francesco Marampon, Vincenzo Tombolini
AIM: To report long term oncologic outcomes after adjuvant radiotherapy (RT) for stage I seminoma. METHOD: We reviewed the complete data set for all patients treated at our institute between 1988 and 2005 for stage I seminoma with adjuvant RT after radical orchiectomy . RESULTS: A total of 85 patients were included. The median follow-up was 15 years. The 20-year overall survival (OS) and relapse free survival (RFS) were 92% and 96.3%, respectively...
August 18, 2016: Oncotarget
Madhur Nayan, Michael A S Jewett, Ali Hosni, Lynn Anson-Cartwright, Philippe L Bedard, Malcolm Moore, Aaron R Hansen, Peter Chung, Padraig Warde, Joan Sweet, Martin O'Malley, Eshetu G Atenafu, Robert J Hamilton
BACKGROUND: Patients on surveillance for clinical stage I (CSI) testicular cancer are counseled regarding their baseline risk of relapse. The conditional risk of relapse (cRR), which provides prognostic information on patients who have survived for a period of time without relapse, have not been determined for CSI testicular cancer. OBJECTIVE: To determine cRR in CSI testicular cancer. DESIGN, SETTING, AND PARTICIPANTS: We reviewed 1239 patients with CSI testicular cancer managed with surveillance at a tertiary academic centre between 1980 and 2014...
August 12, 2016: European Urology
Richard S Matulewicz, Daniel T Oberlin, Joel Sheinfeld, Joshua J Meeks
OBJECTIVE: To determine trends in management and factors associated with men receiving either chemotherapy or radiation therapy post-orchiectomy for Clinical Stage I (CSI) seminoma in a contemporary setting. METHODS AND MATERIALS: The National Cancer Data Base was queried for all patients with CSI seminoma from 1998 to 2012. Adjuvant treatment after orchiectomy was classified into three groups: surveillance, radiotherapy (XRT), and chemotherapy (chemo). Yearly trends in management are described...
August 12, 2016: Urology
Z Cierna, M Mego, I Jurisica, K Machalekova, M Chovanec, V Miskovska, D Svetlovska, K Kalavska, K Rejlekova, K Kajo, J Mardiak, P Babal
BACKGROUND: Germ cell neoplasia in situ (GCNIS), is preinvasive stage of testicular germ cell tumours (TGCTs). Fibrillins, which are integral components of microfibrils are suggested to be involved in cancer pathogenesis and maintenance of embryonic stem cells pluripotency. The aim of this study was to examine fibrillin-1 (FBN-1) expression in TGCTs patients. METHODS: Surgical specimens from 203 patients with TGCTs were included into the translational study. FBN-1 expression was evaluated in the tumour tissue, in GCNIS and in adjacent non-neoplastic testicular tissue in all available cases...
2016: BMC Cancer
A Hosni, P Warde, M Jewett, P Bedard, R Hamilton, M Moore, M Nayan, R Huang, E G Atenafu, M O'Malley, J Sweet, P Chung
AIMS: To identify the characteristics and outcomes associated with late relapse in stage I seminoma. MATERIALS AND METHODS: A retrospective review was carried out of all patients with stage I seminoma managed at our institution between 1981 and 2011. Data were obtained from a prospectively maintained database. Late relapse was defined as tumour recurrence > 2 years after orchiectomy. RESULTS: Overall, 1060 stage I seminoma patients were managed with active surveillance (n=766) or adjuvant radiotherapy (n=294)...
October 2016: Clinical Oncology: a Journal of the Royal College of Radiologists
Emre Tüzel
No abstract text is available yet for this article.
2016: Central European Journal of Urology
Martina Ondrusova, Sona Balogova, Viera Lehotska, Karol Kajo, Bela Mrinakova, Dalibor Ondrus
INTRODUCTION: Following orchiectomy patients with clinical stage I (CSI) testicular seminoma may be managed by active surveillance (AS) or adjuvant treatment (radiotherapy or chemotherapy). In view of the published data on long-term toxicity, mainly second malignant neoplasms (SMNs), adjuvant radiotherapy (ART) is currently no longer recommended as adjuvant therapy for these patients. The purpose of our recent study was to compare the impact of two selected treatment approaches - AS versus adjuvant chemotherapy (ACT) on survival in patients with CSI testicular seminoma...
2016: Central European Journal of Urology
T Tandstad, O Ståhl, O Dahl, H S Haugnes, U Håkansson, Å Karlsdottir, A Kjellman, C W Langberg, A Laurell, J Oldenburg, A Solberg, K Söderström, U Stierner, E Cavallin-Ståhl, R Wahlqvist, N Wall, G Cohn-Cedermark
BACKGROUND: The purpose of the protocol was to reduce the treatment burden in clinical stage I (CSI) seminoma by offering risk-adapted treatment. The protocol aimed to prospectively validate the proposed risk factors for relapse, stromal invasion of the rete testis and tumor diameter >4 cm, and to evaluate the efficacy of one course of adjuvant carboplatin. PATIENTS AND METHODS: From 2007 to 2010, 897 patients were included in a prospective, population-based, risk-adapted treatment protocol implementing one course of adjuvant carboplatin AUC7 (n = 469) or surveillance (n = 422)...
July 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Mette Saksø Mortensen, Jakob Lauritsen, Maria Gry Gundgaard Kier, Mikkel Bandak, Ane Lindegaard Appelt, Mads Agerbæk, Niels Vilstrup Holm, Mette Moe Kempel, Hans von der Maase, Gedske Daugaard
BACKGROUND: Comprehensive data on late relapse (LR) and very LR (VLR) in patients with clinical stage I (CS-1) testicular cancer followed on surveillance are missing. These data are essential for planning optimal follow-up. OBJECTIVE: Assess incidence and outcome of LR (>2 yr) and VLR (>5 yr) in a large cohort of CS-1 surveillance patients, and examine differences in the clinical characteristics of patients with early relapse (ER), LR, and VLR. DESIGN, SETTING, AND PARTICIPANTS: CS-1 surveillance patients diagnosed between 1984 and 2007 were identified from the retrospective Danish Testicular Cancer (DaTeCa) database...
August 2016: European Urology
Taeko Matsuoka, Koji Kawai, Satoshi Ando, Shintaro Sugita, Shuya Kandori, Takahiro Kojima, Jun Miyazaki, Hiroyuki Nishiyama
OBJECTIVE: DNA methyltransferase 3-like plays an important role in germ cell development. The aim of this study was to analyse the DNA methyltransferase 3-like protein expression in testicular germ cell tumors. METHODS: The immunohistochemical expression of DNA methyltransferase 3-like was examined in 86 testicular germ cell tumor specimens in various clinical settings. The association between DNA methyltransferase 3-like expression and disease stage was analyzed...
May 2016: Japanese Journal of Clinical Oncology
Ken-Ichi Harada, Hideaki Miyake, Takayoshi Ogawa, Taka-Aki Inoue, Masato Fujisawa
BACKGROUND: The objective of this study was to retrospectively review oncological outcomes in patients with stage I testicular germ cell tumor (GCT). PATIENTS AND METHODS: This study included 265 consecutive Japanese men undergoing orchiectomy for stage I testicular GCT, and a retrospective review of their records was performed. RESULTS: Of these 265 patients, 192 and 73 were pathologically classified with seminoma and nonseminoma, respectively...
July 2015: Current Urology
Nicholas G Cost, Brian T Caldwell, Mehrad Adibi, Ganesh V Raj, Arthur I Sagalowsky, Vitaly Margulis
PURPOSE: Oncologic outcomes in advanced testicular cancer (TC) depend on appropriate and timely care. Often this care is referred to tertiary academic medical centers (AMCs). The aim of this study was to compare oncologic outcomes of adolescent and young adult (AYA) patients with TC treated from the outset at an AMC to those whose care was initiated elsewhere with subsequent referral. METHODS: An institutional TC database was reviewed, and those AYA patients initiating TC care either inside or outside an AMC were compared...
September 2016: Journal of Adolescent and Young Adult Oncology
Jerome P Richie
No abstract text is available yet for this article.
February 2016: Journal of Urology
Ildar V Gainetdinov, Sofia A Kondratieva, Yulia V Skvortsova, Marina V Zinovyeva, Elena A Stukacheva, Alexey Klimov, Alexey A Tryakin, Tatyana L Azhikina
PIWI pathway proteins are expressed during spermatogenesis where they play a key role in germ cell development. Epigenetic loss of PIWI proteins expression was previously demonstrated in testicular germ cell tumors (TGCTs), implying their involvement in TGCT development. In this work, apart from studying only normal testis and TGCT samples, we also analyzed an intermediate stage, i.e. preneoplastic testis tissues adjacent to TGCTs. Importantly, in this study, we minimized the contribution of patient-to-patient heterogeneity by using matched preneoplastic/TGCT samples...
April 19, 2016: Oncotarget
Jonathan T Wingate, Ruth Etzioni, Dusten M Macdonald, Timothy C Brand
BACKGROUND: The practice patterns for adjuvant therapies for stage I seminoma are rapidly evolving, and surveillance is currently preferred. How these recommendations have affected contemporary practice in an equal-access US population is unknown. MATERIALS AND METHODS: A total of 436 men diagnosed with clinical stage IA-IB seminoma from 2001 to 2011 were identified in the Automated Central Tumor Registry (ACTUR). The ACTUR is the cancer registry system for the Department of Defense...
December 21, 2015: Clinical Genitourinary Cancer
Alberto Diminutto, Umberto Basso, Marco Maruzzo, Franco Morelli, Ugo De Giorgi, Alessandra Perin, Anna Paola Fraccon, Giovanni Lo Re, Anna Rizzi, Teodoro Sava, Giuseppe Fornarini, Francesca Valcamonico, Fable Zustovich, Francesco Massari, Elisa Zanardi, Anna Roma, Filiberto Zattoni, Vittorina Zagonel
BACKGROUND: The administration of carboplatin AUC 7 has become a standard adjuvant option for patients undergoing orchiectomy for stage I seminoma, in alternative to radiotherapy on retroperitoneal lymphnodes or surveillance. The toxicity of AUC 7 carboplatin appeared manageable in the pivotal trial of Oliver et al, but dose ranges were not reported. Fear of toxicity may induce arbitrary dose reductions, which may potentially compromise patients' outcome. PATIENTS AND METHODS: We reviewed adjuvant carboplatin administration in 115 stage I seminoma patients followed in 11 Italian medical oncology centers since 2005...
April 2016: Clinical Genitourinary Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"